A5082541514- SARS-CoV-2 and COVID-19 Research
- Immunodeficiency and Autoimmune Disorders
- Viral gastroenteritis research and epidemiology
- Hepatitis B Virus Studies
- Respiratory viral infections research
- vaccines and immunoinformatics approaches
- COVID-19 Clinical Research Studies
- Metabolism and Genetic Disorders
- SARS-CoV-2 detection and testing
- Animal Virus Infections Studies
- Pneumonia and Respiratory Infections
- Hepatitis C virus research
- Vaccine Coverage and Hesitancy
- Viral Infections and Outbreaks Research
- Veterinary Orthopedics and Neurology
- Bone fractures and treatments
- Renal function and acid-base balance
- Orthopedic Surgery and Rehabilitation
- Musculoskeletal synovial abnormalities and treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Immunotherapy and Immune Responses
- Blood disorders and treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Polyomavirus and related diseases
- HIV/AIDS drug development and treatment
Gilead Sciences (United States)
2024-2025
Vaxart (United States)
2021-2023
Universidad Nacional de Asunción
2010-2018
Transmission-blocking strategies that slow the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and protect against disease 2019 (COVID-19) are needed. We have developed an orally delivered adenovirus type 5-vectored SARS-CoV-2 vaccine candidate expresses spike protein. Here, we demonstrated hamsters vaccinated by oral or intranasal route had robust cross-reactive antibody responses. then induced a postvaccination infection inoculating with SARS-CoV-2. Orally...
As new SARS-CoV-2 variants continue to emerge, it is important evaluate the potency of antiviral drugs support their continued use. Remdesivir (RDV; VEKLURY®) an approved treatment for COVID-19, and obeldesivir (ODV) are inhibitors RNA-dependent RNA polymerase Nsp12. Here we show these two compounds retain activity against Omicron BA.2.86, BF.7, BQ.1, CH.1.1, EG.1.2, EG.5.1, EG.5.1.4, FL.22, HK.3, HV.1, JN.1, JN.1.7, JN.1.18, KP.2, KP.3, LB.1, XBB.1.5, XBB.1.5.72, XBB.1.16, XBB.2.3.2,...
Abstract Background Remdesivir (RDV), a nucleotide analog prodrug that targets the viral RNA-dependent RNA polymerase, Nsp12, is approved to treat COVID-19 in hospitalized and nonhospitalized patients. Obeldesivir (ODV), an oral mono-5’-isobutyryl ester prodrug, metabolized into same active triphosphate as RDV. The antiviral activity of RDV ODV against previous Omicron subvariants (BA.1 XBF) was maintained with respect ancestral WA1 strain. Here, data recent (XBB.2.3.2, EG.5.1, EG.1.2,...
Respiratory syncytial virus (RSV) is a significant cause of morbidity and mortality in high-risk populations. Although prophylactic options are available, there no effective oral therapeutics for RSV infection. Obeldesivir (ODV) an orally bioavailable prodrug the nucleoside analog GS-441524, which converted intracellularly to its active triphosphate inhibits RNA polymerase. Here we report potent antiviral activity ODV against geographically temporally diverse A B clinical isolates (EC 50 :...
Vaccines that are shelf stable and easy to administer crucial improve vaccine access reduce severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission around the world.In this study, we demonstrate an oral, adenovirus-based candidate protects against SARS-CoV-2 in a Syrian hamster challenge model.Hamsters administered doses of VXA-CoV2-1 showed reduction weight loss lung pathology had completely eliminated infectious virus 5 days postchallenge. Oral immunization induced...
Abstract Background Remdesivir (RDV) is a nucleotide analog prodrug approved for treatment of COVID-19. Here we present comprehensive SARS-CoV-2 resistance analyses from all cohorts the Phase 2/3 CARAVAN study, which demonstrated safety RDV COVID-19 in pediatric participants birth to < 18 years age. Methods was single-arm, open-label study wherein received IV ≤10 days. Full-genome deep sequencing performed on respiratory samples collected Days 1 (baseline), 3, 5, 7, and/or 10. In...
Abstract Background Despite the plethora of efficacious vaccines to initial Wuhan strain SARS-CoV-2, these do not induce robust mucosal immunity, offering limited protection against breakthrough infection and replication in respiratory tract. The mucosa is first line defense, therefore a vaccine that induces IgA response could be an important strategy curbing global pandemic. Methods We conducted single-site, dose-ranging, open-label clinical trial oral SARS-CoV-2 determine safety...
SARS-CoV-2 variant clades continue to circumvent antibody responses elicited by vaccination or infection. Current parenteral strategies reduce illness and hospitalization, yet do not significantly protect against infection the more recent variants. It is thought that mucosal may better inducing immunity at sites of infection, blocking viral transmission effectively, inhibiting evolution new variants concern (VOCs). In this study, we evaluated immunogenicity efficacy a mucosally-delivered,...
Abstract Transmission-blocking strategies that slow the spread of SARS-CoV-2 and protect against COVID-19 are needed. We have developed a shelf-stable, orally-delivered Ad5-vectored vaccine candidate expresses spike protein. Here we demonstrated oral intranasal vaccination this protected disease in index hamsters, decreased aerosol transmission to unvaccinated, naïve hamsters. confirmed mucosally-vaccinated hamsters had robust antibody responses. then induced post-vaccination infection by...
Abstract The emergence of SARS-CoV-2 variants continues to be a major obstacle for controlling the global pandemic. Despite currently authorized vaccines ability reduce severe disease and hospitalization, new immunization strategies are needed that enhance mucosal immune responses, inhibit community transmission, provide protection against emerging variants. We have developed mucosally delivered, non-replicating recombinant adenovirus vector (rAd5) vaccine, has proven efficacy in clinic...
Abstract Background Covid-19 has accelerated global demand for easily distributed vaccines. Furthermore, as variant SARS-CoV-2 strains that circumvent antibody responses emerge, cross-protective vaccines provide substantial public health benefits. Vaxart is developing a shelf stable oral tablet vaccine incorporates both the spike (S) and more conserved nucleocapsid (N) proteins. Vaxart’s platform uses non-replicating adenovirus TLR3 agonist an adjuvant. Methods In open-label phase 1 clinical...
<h3>Background</h3> TAF resistance has not been detected after up to three years of treatment in CHB patients. Here, we report results from annual surveillance 3 through 8 treatment. <h3>Methods</h3> Two randomized, double-blind (DB), active-controlled trials evaluate hepatitis e antigen (HBeAg)-negative and HBeAg-positive participants with were conducted over (384 weeks). Sequence analysis the pol/RT region was attempted for any participant who experienced a viral breakthrough, blip, or...
El objetivo del estudio fue determinar la evolución clÃnica y radiológica post quirúrgica de un caso fractura completa cerrada a tercer fragmento fémur en animal especie felina, común europeo, hembra 1 año edad, utilizando clavo endomedular Steinmann acero inoxidable cerclajes con cintillos poliamida. Los implantes poliamida proporcionaron gran fuerza compresión que vencieron adecuadamente rotación hueso fracturado, dando estabilidad secundaria al foco fractura. Se realizaron...